$BEAM News

Beam Therapeutics (BEAM) Is Up 17.6% After Advancing BEAM-302 Toward Accelerated Approval in AATD

Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript

Beam Therapeutics Inc. (BEAM) Presents at ATS 2026 International Conference - Slideshow

Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances

Two Programs That Could Make or Break Beam Therapeutics Inc (BEAM) Stock

Beam Therapeutics Data Puts BEAM 302 And AAT Disease In Focus

Beam Therapeutics Presents Recently Reported Topline Clinical Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the American Thoracic Society (ATS) 2026 International Conference

Beam Therapeutics Presented Clinical Data From Phase 1/2 Trial For BEAM-302 Treatment For Alpha-1 Antitrypsin Deficiency At American Thoracic Society International Conference In Orlando, FL

Beam Therapeutics Supports AlphaDetect to Accelerate Detection of Alpha-1

Bernstein Maintains Outperform on Beam Therapeutics, Lowers Price Target to $39

Beam Therapeutics to Present at 2026 RBC Capital Markets Global Healthcare Conference

Beam Therapeutics to Present Updated Biomarker Data from Phase 1/2 BEACON Trial Further Underscoring Risto-cel’s Ability to Restore Red Blood Cell Health and Function in Sickle Cell Disease at EHA2026

Earnings Update: Beam Therapeutics Inc. (NASDAQ:BEAM) Just Reported And Analysts Are Boosting Their Estimates

BEAM's Q1 Loss Wider Than Expected, Revenues Beat Estimates

Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Beats Revenue Estimates

Wave Life Sciences: Good Platform, Mixed Clinical Trial Data, Hold

Beam Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates

Beam Therapeutics Q1 EPS $(0.91) Beats $(1.09) Estimate, Sales $31.738M Beat $10.977M Estimate

Why Beam Therapeutics (BEAM) Is Up 5.3% After TIME100 Spotlight and Vanguard Stake Disclosure

Beam Therapeutics’ TIME Honor Puts Base Editing And Valuation In Focus